Theravance Biopharma, Inc. Proceeds from Sale of Productive Assets
Theravance Biopharma, Inc. (TBPH) reported Proceeds from Sale of Productive Assets of $5.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2020-02-27
- Theravance Biopharma, Inc. proceeds from sale of productive assets for the quarter ending 2019-12-31 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale of productive assets for the quarter ending 2018-12-31 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale of productive assets for the quarter ending 2018-09-30 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale of productive assets for the quarter ending 2018-06-30 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale of productive assets for fiscal 2019 was $5.00K, a 70.59% decline from fiscal 2018.
- Theravance Biopharma, Inc. proceeds from sale of productive assets for fiscal 2018 was $17.00K.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $5.00K 10-K · filed 2020-02-27 | ||
| 2019-09-30 | $5.00K 10-Q · filed 2019-11-08 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $17.00K 10-K · filed 2020-02-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $17.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $17.00K 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $17.00K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |